Literature DB >> 33052842

PI-RADSv2.1: Current status.

Stephanie M Walker1, Barış Türkbey1.   

Abstract

Multiparametric magnetic resonance imaging (mpMRI) has played an increasing role in the detection and local staging of prostate cancer over the last 15 years. Prostate mpMRI, due to various factors, is prone to high inter-reader variability necessitating standardized reporting guidelines that provide accurate and actionable information to the ordering clinician. The Prostate Imaging-Reporting and Data System version 2.1 (PI-RADSv2.1) was released in March 2019 as an update to PI-RADSv2.0 with the hope of further standardizing the reporting process of prostate mpMRI, improving the detection of clinically significant cancer, reducing the biopsy rate of indolent tumors, and decreasing inter-reader variability. Early data show an improved performance of PI-RADSv2.1 over PI-RADSv2.0. Updates included in PI-RADSv2.1 and its current experience in clinic will be reviewed in this review.

Entities:  

Year:  2020        PMID: 33052842      PMCID: PMC8057356          DOI: 10.5152/tud.2020.20403

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  29 in total

1.  Can Apparent Diffusion Coefficient Values Assist PI-RADS Version 2 DWI Scoring? A Correlation Study Using the PI-RADSv2 and International Society of Urological Pathology Systems.

Authors:  Sonia Gaur; Stephanie Harmon; Lauren Rosenblum; Matthew D Greer; Sherif Mehralivand; Mehmet Coskun; Maria J Merino; Bradford J Wood; Joanna H Shih; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  AJR Am J Roentgenol       Date:  2018-05-07       Impact factor: 3.959

2.  A Dedicated Prostate MRI Teaching Course Improves the Ability of the Urologist to Interpret Clinically Significant Prostate Cancer on Multiparametric MRI.

Authors:  Veeru Kasivisvanathan; Alessandro Ambrosi; Francesco Giganti; Edwin Chau; Alex Kirkham; Shonit Punwani; Clare Allen; Mark Emberton; Caroline M Moore
Journal:  Eur Urol       Date:  2018-10-14       Impact factor: 20.096

3.  How does PI-RADS v2.1 impact patient classification? A head-to-head comparison between PI-RADS v2.0 and v2.1.

Authors:  Ana Sofia Linhares Moreira; Pieter De Visschere; Charles Van Praet; Geert Villeirs
Journal:  Acta Radiol       Date:  2020-07-23       Impact factor: 1.990

4.  Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: Comparison between readers with different experience.

Authors:  Eleonora Di Campli; Andrea Delli Pizzi; Barbara Seccia; Roberta Cianci; Martina d'Annibale; Antonella Colasante; Sebastiano Cinalli; Pietro Castellan; Riccardo Navarra; Romina Iantorno; Daniela Gabrielli; Angelica Buffone; Massimo Caulo; Raffaella Basilico
Journal:  Eur J Radiol       Date:  2018-02-01       Impact factor: 3.528

5.  Postoperative Biochemical Failure in Patients With PI-RADS Category 4 or 5 Prostate Cancers: Risk Stratification According to Zonal Location of an Index Lesion.

Authors:  Nari Shin; Sung Yoon Park
Journal:  AJR Am J Roentgenol       Date:  2020-07-08       Impact factor: 3.959

6.  mp-MRI Prostate Characterised PIRADS 3 Lesions are Associated with a Low Risk of Clinically Significant Prostate Cancer - A Retrospective Review of 92 Biopsied PIRADS 3 Lesions.

Authors:  Heath Liddell; Rajeev Jyoti; Hodo Z Haxhimolla
Journal:  Curr Urol       Date:  2015-07-10

Review 7.  Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2.

Authors:  Baris Turkbey; Andrew B Rosenkrantz; Masoom A Haider; Anwar R Padhani; Geert Villeirs; Katarzyna J Macura; Clare M Tempany; Peter L Choyke; Francois Cornud; Daniel J Margolis; Harriet C Thoeny; Sadhna Verma; Jelle Barentsz; Jeffrey C Weinreb
Journal:  Eur Urol       Date:  2019-03-18       Impact factor: 20.096

8.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

9.  PI-RADS® Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance.

Authors:  Alex Z Wang; Luke P O’Conno; Nitin K Yerram; Lori Long; Johnathan Zeng; Sherif Mehralivand; Stephanie A Harmon; Amir H Lebastchi; Michael Ahdoot; Patrick T Gomella; Sandeep Gurram; Peter L Choyke; Maria J Merino; Joanna H Shih; Bradford J Wood; Baris Turkbey; Peter A Pinto
Journal:  J Urol       Date:  2020-07-27       Impact factor: 7.450

10.  Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.

Authors:  Christopher S Lim; Jorge Abreu-Gomez; Ivan Carrion; Nicola Schieda
Journal:  AJR Am J Roentgenol       Date:  2021-01-21       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.